To help launch a new prescription medication for Irritable Bowel Syndrome with Diarrhea (IBS-D), we developed a quirky, disruptive character named Irritabelle.
She appears at the worst possible times, messes with your life, and is, well...irritating. Irritabelle gives a voice to the often difficult relationship IBS-D sufferers have with their gut.
We added content on the web, putting Irritabelle to work explaining the facts of IBS-D. We even had an intervention.
2016 Clio Health: Integrated Campaign Bronze
April 14, 2016 Adweek's Ad of the Day
In March 2022, Florida passed the Parental Rights in Education Act which prohibits public schools from having classroom discussion about sexual orientation or gender identity. Opponents dubbed it the “Don’t Say Gay” law, and it threatened to throw the mental health of LGBTQ+ students into complete disarray. Research showed that laws like this create feelings of exclusion, instill a sense of shame, and increase risk for depression, self-harm, and suicide.
Live Out Load, a non-profit dedicated to supporting LGBTQ+ youth, refused to stay silent. They wanted to let the students know that while their politicians don’t want to talk about it, there’s a whole community across the country that does. So we took the symbol of Florida - the orange - and turned it into a symbol of defiance. An orange wedge in your mouth acts like a gag. But when removed, our voices can be heard loud and proud, giving these students a sense of pride, purpose, and community.
Not all trucking businesses are the same, and a lot of how fleet managers outfit their trucks depends on what they carry. As a part of their Application Specific Solutions offering, Volvo Trucks was looking for a way to highlight a range of nuanced powertrain options that help to maximize fuel efficiency by perfectly matching power to application.
In order to help break down a complex product benefit, we developed a series of videos designed to show the absurdity of using too much power for job. After the video, fleet managers are driven to a survey that helps them identify the right torque package for their specific business.
There have been no measurable advancements in the treatment of partial-onset seizures in the last 20 years AND nearly 60% of the 3 million U.S. adults with epilepsy are still experiencing seizures, despite taking epilepsy medication. People with epilepsy have been forced to settle for “good enough” and physicians have had to compromise for so long, they’ve grown complacent.
We believe that one seizure is one too many and that every person with epilepsy deserves the possibility of getting to zero seizures. We determined that if healthcare professionals could step into their patients’ shoes and experience life from their perspective, even for a moment, that they would quickly come to the conclusion that any seizure, even the occasional one, is simply unacceptable.
In the first 8 months, nearly 5,000 people have been prescribed XCOPRI making it the most successful launch of an AED in the last 20 years. Visitors spent over 6 minutes a session on our website and 25% of users came back for another look. Both are significantly higher than industry standard.
Despite there being several new anti-epileptic drugs entering the market over the past two decades, 1.8 million adults in the United States continue to be held captive by their seizures. To build awareness of the magnitude of uncontrolled epilepsy among healthcare professionals, we personified the disease as C. Zure, a serial hostage taker holding all adults with uncontrolled epilepsy captive.
In keeping with the psyche of a madman, the campaign started with a journal ad designed to resemble a ransom note. At conferences, we turned our booth into an escape room designed to look like C. Zure’s lair, inviting docotors to see what it’s like to be held captive by this predator. Once inside, they were given clues based on patient profiles and CDC reprints, all intended to help build empathy for their patients and encourage the reassessment of their current approach to treatment.
For up to 50% of patients, the cause of severe asthma has nothing to do with allergies and everything to do with one tiny immune cell — the eosinophil.
We needed physicians to see the damage eosinophils are doing to their patients’ lungs and pay closer attention to high eosinophil counts on routine blood tests they are already doing. This key measurement that indicates the cause of the disease is being overlooked by 73% of allergists.
Our challenge: Make the invisible visible.
2017 Clio Health: Integrated Campaign (Pharmaceutical) Short List
When Sanofi and Regeneron tasked us to raise awareness of uncontrolled high cholesterol, the #1 contributing factor to heart disease, we knew traditional healthcare advertising wouldn’t work. Because high cholesterol is a condition without symptoms. You can't see it, or feel it, so you forget it. And that's the last thing we wanted our patients to do.
So, we made a movie. We used entertainment as a vehicle to tell our story and gave a "face" to high cholesterol. A feature-length film by Academy Award winner, Cynthia Wade, set out to tell the human side of this unseen disease. It showed the global reach, the human impact, the triumphs and the failures of patients, caregivers, medical experts, policy makers, advocates, the famous, and the ordinary. Heart Felt was released in July 2015.
But the film was just the beginning. The real impact could be found on TakeDownCholesterol.com itself. Which we populated with educational materials and over 30 short form videos that delivered heart healthy tips from the experts featured in the film.
Every year, approximately 10,000 people in the Unites States are diagnosed with myelodysplastic syndromes (MDS), a type of blood cancer that can result in chronic anemia that leaves patients exhausted and unable to do basic, everyday tasks.
People with lower-risk myelodysplastic syndromes (LR-MDS) are not considered urgent to many HemOncs. To make matters worse, 1 in 3 patients with MDS do not respond to the standard of care (ESAs) and those who do, often relapse—leaving patients with no option, other than a lifetime reliance on blood transfusions. You can imagine the impact that has on a patient’s quality of life.
We created an unbranded awareness campaign that challenges this complacent mindset and behavior to increase a sense of urgency around diagnosis and the need for a more aggressive form of treatment. For HemOncs who want something better for their patients, they need to think outside the bag.
In life, there are things you want to touch. And some... you just don't. Introducing the Kohler Touchless Toilet, the no-touch flush for your home.
To announce the exclusive availability of the new Kohler Touchless Toilet at The Home Depot, we developed an idea that showcased the amazing new technology in the only place you could get it.
The odds are stacked against the epilepsy community. Despite multiple treatment options, 60% of the 3 million U.S. adults with epilepsy who are prescribed antiepileptic drugs (AEDs) are still seizing. They’ve been forced to accept “good enough” when it comes to their treatment and life.
People with epilepsy are not quitters—they’re fighters. But, they needed something they could rally around. So, we built a campaign that empowered them to fight for better control and ask their doctor for XCOPRI. Seeing themselves portrayed as heroes has inspired the epilepsy community to join in the fight for better seizure control and discover the possibility of ZERO seizures.
In the first 8 months, nearly 5,000 people have joined the fight with XCOPRI, making it one of the most successful launches of an AED in the last 20 years, all during a global pandemic. Over 125,000 users visited our website since May 2020 to watch videos, download resources and learn about the possibility of zero seizures.
3.4 million people in the U.S. suffer from epilepsy. Most have no idea when their next seizure will be. There are no shortage of devices to record seizures when they happen, but what if we could predict seizures BEFORE they happen? Working in partnership with the Health Innovation Lab at the University of Delaware, we’ve built a working prototype and have a patent pending on this exciting new technology.
